Founded in 1996, Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure (CHF). Impulse Dynamics’s operations are spread throughout the globe, with corporate headquarters in the Netherlands Antilles, New York based US operations, and Germany based EU operations (Stuttgart).

Impulse Dynamics’s products are based on its proprietary technology for administrating Cardiac Contractility Modulation (CCM) therapy admitted in European Society of Cardiology Guidelines. This form of treatment has been shown in clinical trials to produce an immediate and powerful modulating effect on cardiac cells, resulting in a significant increase in cardiac performance.

Impulse Dynamics has obtained over 120 patents, covering the concepts, signals, effects, algorithms, systems and designs of the CCM products. It’s the only company that provides CCM solutions to heart failure patients.

The founder of Impulse Dynamics, Professor Shlomo Ben-Haim, has made multiple successes in his inventions by global commercialization and exit to large medical companies such as Johnson & Johnson and Medtronic. He has held faculty appointments at both Harvard University and the Technion– Israel Institute of Technology.

The Optimizer, the Impulse Dynamics’s first product, has been successfully launched in Europe, and has been implanted in over 3,000 patients with over 8 years of follow-up data available. The Optimizer with CCM therapy, is CE marked and is in the process of obtaining approvals in the US (expected 2017), China (expected 2017) and Japan (expected 2019).

In May 2016, TCC Capital together with Hong Kong’s Henderson Group and other Hong Kong investors co-invested USD 30m in Impulse Dynamics.

TCC Capital exits the investment in Impulse Dynamics successfully in June 2017.